Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carotuximab + everolimus + letrozole
- Development stage
- Unknown
- Lead developer
- TRACON Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of carotuximab (a monoclonal antibody targeting endoglin), everolimus (an mTOR inhibitor), and letrozole (an aromatase inhibitor). The combination was studied for preoperative treatment in hormone receptor-positive and HER2-negative breast cancer. Carotuximab targets endoglin, which is involved in angiogenesis, while everolimus inhibits the PI3K/AKT/mTOR pathway, and letrozole reduces estrogen production by inhibiting aromatase. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab, with carotuximab accelerating the biodistribution and clearance of everolimus.
- Other names
- carotuximab IV (ENV-105) + everolimus + letrozole
02
Targets
CYP19A1 (Aromatase)Mechanistic target of rapamycin complex 1ENG (Integrin Beta 6)
Beyond the preview
Go deeper on carotuximab + everolimus + letrozole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carotuximab + everolimus + letrozole.